<http://schema.org/description>
"A seemingly late start had most thinking Bristol-Myers Squibb&amp;#039;s hepatitis C drug daclatasvir would prove an also-ran in the race for market share. But a savvy move to focus overseas and"^^<http://www.w3.org/2001/XMLSchema#string>
<http://www.aol.com/article/2014/01/15/bristols-daclatasvir-may-prove-a-winner/20808645/>